Compare AAP & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAP | LIVN |
|---|---|---|
| Founded | 1929 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.5B |
| IPO Year | 2002 | 2015 |
| Metric | AAP | LIVN |
|---|---|---|
| Price | $58.08 | $63.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 7 |
| Target Price | $53.50 | ★ $72.43 |
| AVG Volume (30 Days) | ★ 1.2M | 651.9K |
| Earning Date | 05-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | ★ 113.01 | N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $8,601,000,000.00 | N/A |
| Revenue This Year | $0.35 | $9.79 |
| Revenue Next Year | $2.51 | $6.63 |
| P/E Ratio | $79.52 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.84 | $35.00 |
| 52 Week High | $70.00 | $71.58 |
| Indicator | AAP | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 60.27 | 48.36 |
| Support Level | $57.77 | $61.63 |
| Resistance Level | $62.28 | $65.61 |
| Average True Range (ATR) | 2.11 | 1.94 |
| MACD | 0.28 | 0.05 |
| Stochastic Oscillator | 68.03 | 34.20 |
Advance Auto Parts is a leading auto-parts retailer in North America with more than 4,000 store and branch locations. About half of the firm's sales are geared toward the professional channel, with the remaining sales in the do-it-yourself market. Through its vast store footprint and distribution network, Advance manages thousands of stock-keeping units for various vehicle makes and models. The retailer primarily competes on inventory availability and service speed, making the operating efficiency of its hub-and-spoke distribution model critical to meeting customer needs.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.